Claims-Based Algorithm to Identify Pre-Exposure Prophylaxis Indications for Tenofovir Disoproxil Fumarate and Emtricitabine Prescriptions (2012-2014): Validation Study

Overview

Journal JMIR Form Res

Publisher JMIR Publications

Specialty Biomedical Engineering

Date 2024 Aug 14

PMID 39141024

Authors

Patrick Sean Sullivan

Robertino M Mera-Giler

Staci Bush

Valentina Shvachko

Eleanor Sarkodie

Daniel OFarrell

Stephanie Dubose

David Magnuson

Affiliations

Soon will be listed here.

Abstract

Background: To monitor the use of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and related medicines for pre-exposure prophylaxis (PrEP) as HIV prevention using commercial pharmacy data, it is necessary to determine whether TDF/FTC prescriptions are used for PrEP or for some other clinical indication.

Objective: This study aimed to validate an algorithm to distinguish the use of TDF/FTC for HIV prevention or infectious disease treatment.

Methods: An algorithm was developed to identify whether TDF/FTC prescriptions were for PrEP or for other indications from large-scale administrative databases. The algorithm identifies TDF/FTC prescriptions and then excludes patients with International Classification of Diseases (ICD)-9 diagnostic codes, medications, or procedures that suggest indications other than for PrEP (eg, documentation of HIV infection, chronic hepatitis B, or use of TDF/FTC for postexposure prophylaxis). For evaluation, we collected data by clinician assessment of medical records for patients with TDF/FTC prescriptions and compared the assessed indication identified by the clinician review with the assessed indication identified by the algorithm. The algorithm was then applied and evaluated in a large, urban, community-based sexual health clinic.

Results: The PrEP algorithm demonstrated high sensitivity and moderate specificity (99.6% and 49.6%) in the electronic medical record database and high sensitivity and specificity (99% and 87%) in data from the urban community health clinic.

Conclusions: The PrEP algorithm classified the indication for PrEP in most patients treated with TDF/FTC with sufficient accuracy to be useful for surveillance purposes. The methods described can serve as a basis for developing a robust and evolving case definition for antiretroviral prescriptions for HIV prevention purposes.

References

Bunting S, Hunt B, Boshara A, Jacobs J, Johnson A, Hazra A . Examining the Correlation Between PrEP Use and Black:White Disparities in HIV Incidence in the Ending the HIV Epidemic Priority Jurisdictions. J Gen Intern Med. 2022; 38(2):382-389. PMC: 9905374. DOI: 10.1007/s11606-022-07687-y. View

Ojikutu B, Bogart L, Mayer K, Stopka T, Sullivan P, Ransome Y . Spatial Access and Willingness to Use Pre-Exposure Prophylaxis Among Black/African American Individuals in the United States: Cross-Sectional Survey. JMIR Public Health Surveill. 2019; 5(1):e12405. PMC: 6378549. DOI: 10.2196/12405. View

Fauci A, Redfield R, Sigounas G, Weahkee M, Giroir B . Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019; 321(9):844-845. DOI: 10.1001/jama.2019.1343. View

Mayer K, Molina J, Thompson M, Anderson P, Mounzer K, De Wet J . Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020; 396(10246):239-254. PMC: 9665936. DOI: 10.1016/S0140-6736(20)31065-5. View

Newcombe R . Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17(8):857-72. DOI: 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e. View

Huang Y, Zhu W, Smith D, Harris N, Hoover K . HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016. MMWR Morb Mortal Wkly Rep. 2018; 67(41):1147-1150. PMC: 6193685. DOI: 10.15585/mmwr.mm6741a3. View

Martin-Latry K, Begaud B . Pharmacoepidemiological research using French reimbursement databases: yes we can!. Pharmacoepidemiol Drug Saf. 2010; 19(3):256-65. DOI: 10.1002/pds.1912. View

Dasgupta S, Kramer M, Rosenberg E, Sanchez T, Sullivan P . Development of a comprehensive measure of spatial access to HIV provider services, with application to Atlanta, Georgia. Springerplus. 2016; 5(1):984. PMC: 4932000. DOI: 10.1186/s40064-016-2515-8. View

Sullivan P, Mera Giler R, Mouhanna F, Pembleton E, Guest J, Jones J . Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017. Ann Epidemiol. 2018; 28(12):833-840. PMC: 6286244. DOI: 10.1016/j.annepidem.2018.06.009. View

10.

Landis J, Koch G . The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159-74. View

11.

Molina J, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C . Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2017; 18(3):308-317. DOI: 10.1016/S1473-3099(17)30725-9. View

12.

Krakower D, Gruber S, Hsu K, Menchaca J, Maro J, Kruskal B . Development and validation of an automated HIV prediction algorithm to identify candidates for pre-exposure prophylaxis: a modelling study. Lancet HIV. 2019; 6(10):e696-e704. PMC: 7522919. DOI: 10.1016/S2352-3018(19)30139-0. View

13.

Sullivan P, Mouhanna F, Mera R, Pembleton E, Castel A, Jaggi C . Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions. Ann Epidemiol. 2020; 44:16-30. DOI: 10.1016/j.annepidem.2020.01.004. View

14.

McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

15.

Gruber S, Krakower D, Menchaca J, Hsu K, Hawrusik R, Maro J . Using electronic health records to identify candidates for human immunodeficiency virus pre-exposure prophylaxis: An application of super learning to risk prediction when the outcome is rare. Stat Med. 2020; 39(23):3059-3073. PMC: 7646998. DOI: 10.1002/sim.8591. View

16.

Doherty R, Walsh J, Quinn K, John S . Association of Race and Other Social Determinants of Health With HIV Pre-Exposure Prophylaxis Use: A County-Level Analysis Using the PrEP-to-Need Ratio. AIDS Educ Prev. 2022; 34(3):183-194. PMC: 9196948. DOI: 10.1521/aeap.2022.34.3.183. View

17.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

18.

Smith D, Sullivan P, Cadwell B, Waller L, Siddiqi A, Mera-Giler R . Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016. Clin Infect Dis. 2020; 71(12):3144-3151. PMC: 7819523. DOI: 10.1093/cid/ciz1229. View

19.

Beymer M, Holloway I, Pulsipher C, Landovitz R . Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals. Curr HIV/AIDS Rep. 2019; 16(4):349-358. PMC: 6719717. DOI: 10.1007/s11904-019-00450-9. View

20.

Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L . Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021; 385(7):595-608. PMC: 8448593. DOI: 10.1056/NEJMoa2101016. View